Skip to main content

Table 1 Clinical response rate and pathological response rate to neoadjuvant chemotherapy

From: Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer

pathological response all breast cancer (n = 239) TNBC q(n = 83, 34.7%) non-TNBC (n = 156, 65.3%)
pCR: pathological complete response
 CR: complete response 91 (38.1%) 40 (48.2%) 51 (32.7%)
non-pCR: non-pathological complete response
 PR: partial response 118 (49.4%) 34 (41.0%) 84 (53.8%)
 SD: stable disease 25 (10.5%) 7 (8.4%) 18 (11.5%)
 PD: progressive disease 5 (2.0%) 2 (2.4%) 3 (2.0%)
RR (CR + PR):response rate 209 (87.5%) 74 (89.2%) 135 (86.5%)
  1. TNBC triple-negative breast cancers